These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30581413)

  • 1. Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.
    Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
    Front Neurol; 2018; 9():1071. PubMed ID: 30581413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
    Koudriavtseva T; Sbardella E; Trento E; Bordignon V; D'Agosto G; Cordiali-Fei P
    Clin Exp Immunol; 2014 Jun; 176(3):320-6. PubMed ID: 24387139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
    Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study.
    Bridel C; Beauverd Y; Samii K; Lalive PH
    Neurol Neuroimmunol Neuroinflamm; 2015 Aug; 2(4):e123. PubMed ID: 26140281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.
    Krumbholz M; Meinl I; Kümpfel T; Hohlfeld R; Meinl E
    Neurology; 2008 Oct; 71(17):1350-4. PubMed ID: 18936427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis.
    Cuculiza Henriksen A; Ammitzbøll C; Petersen ER; McWilliam O; Sellebjerg F; von Essen MR; Romme Christensen J
    Mult Scler Relat Disord; 2021 Jul; 52():102987. PubMed ID: 33984651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
    Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
    Front Immunol; 2018; 9():2669. PubMed ID: 30524432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
    PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
    La Gioia S; Seghezzi M; Barcella V; Dominoni P; Mecca T; Frigeni B; Conti MZ; Vedovello M; Vidali M; Rottoli M; Buoro S
    Mult Scler Relat Disord; 2016 Jul; 8():141-4. PubMed ID: 27456890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune surveillance in multiple sclerosis patients treated with natalizumab.
    Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
    Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.
    Bühler U; Fleischer V; Luessi F; Rezk A; Belikan P; Graetz C; Gollan R; Wolf C; Lutz J; Bar-Or A; Siffrin V; Zipp F
    Mult Scler; 2017 Apr; 23(4):567-576. PubMed ID: 27436357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world evidence and patient preference for subcutaneous
    Gold R; Schmidt S; Deisenhammer F; Motte J; Richter N; Taipale K; Salmen HC; Bohland C; Schirduan K
    Ther Adv Neurol Disord; 2024; 17():17562864241241382. PubMed ID: 38616781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.
    van Langelaar J; van der Vuurst de Vries RM; Janssen M; Wierenga-Wolf AF; Spilt IM; Siepman TA; Dankers W; Verjans GMGM; de Vries HE; Lubberts E; Hintzen RQ; van Luijn MM
    Brain; 2018 May; 141(5):1334-1349. PubMed ID: 29659729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and radiological control of highly active relapsing-remitting multiple sclerosis with first-line natalizumab.
    Meca-Lallana JE; Carreón-Guarnizo E; Hernández-Clares R; García-Molina E; Díaz-Pérez J; Leon-Hernández A; Zamarro-Parra J; Martín-Fernández JJ
    Neurodegener Dis Manag; 2017 Jun; 7(3):175-181. PubMed ID: 28592169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.